Combination technique improves polysaccharide characterization
The AF4-MALS-RI method makes possible the accurate determination of molecular weight distribution of polysaccharide macromolecules.
Postnova Analytics reports on a new method for the accurate molecular weight determination of complex polysaccharides (Chitosans) using asymmetric flow field flow fractionation (AF4) coupled with multi-angle light scattering (MALS) and differential refractive index (RI) detectors.
Historically the technique of choice for characterization of polysaccharides has been Size Exclusion Chromatography (SEC). For more complex polysaccharides, such as chitosans, however, employing SEC techniques requires pre-filtration of samples to remove interfering aggregate fractions, which is both time-consuming and can lead to considerable sample loss.
The described AF4-MALS-RI method allows the separation of polymer from molecular aggregates typically found in chitosan solutions making possible the accurate determination of molecular weight distribution of the polysaccharide macromolecules.
A new published paper describes the effect of different experimental conditions on the obtained AF4-MALS-RI results which were compared with those obtained from SEC-MALS-RI. The chitosans analysed in this research were from different biological sources and of varying degree of acetylation.
The authors of the paper conclude that the AF4-MALS-RI method has the advantage of not only allowing the identification and separation of the aggregates present, but also the accurate determination of the MW distribution for a wide range of chitosan’s of varying type where results are well correlated with those obtained by more conventional techniques.
The Postnova AF2000 is a high-performance Asymmetric Flow Field-Flow Fractionation (AF4) platform for separation of nanoparticles, macromolecules such as polysaccharides and proteins in complex matrices. Modular in design, the AF2000 incorporates the combined experience, expertise and technological advances from Postnova Analytics' two decades of leadership in FFF. Incorporating a range of FFF modules in a single integrated system to provide universal separation, the AF2000 offers more flexibility, better performance and more robust results than any system before.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.